A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Clinical trial NCT00913835 · COMPLETED
Trial details
- NCT number
- NCT00913835
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-06-01
- Primary completion
- 2011-10-01
- Enrollment
- 125
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.